A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

This study is testing a new pill called giredestrant to see if it works better than the standard treatment, fulvestrant. Both drugs are being tested in combination with common cancer-growth blockers to help treat advanced breast cancer that has stopped responding to earlier hormone therapies.

This trial is for adults with advanced breast cancer that is estrogen-receptor positive (ER+) and HER2-negative. You must have had your cancer return after previous hormone therapy and have not yet received chemotherapy or immunotherapy for this advanced stage of the disease.

You will be randomly assigned to take either the new drug or the standard treatment, combined with a daily cancer-growth blocker. You will also have a simple blood test to look for specific genetic changes in your cancer cells to help doctors understand how your tumor responds.

The study is currently recruiting patients at specific centers in Daphne, Alabama, and Glendale and Auburn, California. Please talk to your oncologist to see if a location near you is available.